TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor
Brief Summary: Placement of a vaginal pessary reduces significantly the rate of spontaneous preterm birth in pregnant women with short cervical length after an episode of threatened preterm labour.


Options:
A: Arm Label: Expectant Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Placement of cervical pessary since 23 weeks until 37 weeks; Type: EXPERIMENTAL; Interventions: Device: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Device: Silicon ring (Arabin Pessary); Assigned to Arm(s): Placement of cervical pessary since 23 weeks until 37 weeks
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Silicon ring (Arabin Pessary) | Intervention Type: DEVICE; Name: Silicon ring (Arabin Pessary); Assigned to Arm(s): 2
C: Arm Label: Vaginal progesterone and Pessary; Type: EXPERIMENTAL; Interventions: Drug: Arabin Pessary | Arm Label: Vaginal progesterone only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arabin Pessary | Intervention Type: DRUG; Name: Arabin Pessary; Assigned to Arm(s): Vaginal progesterone and Pessary, Vaginal progesterone only
D: Arm Label: Cervical Pessary-Group; Type: EXPERIMENTAL; Interventions: Device: cervical pessary | Arm Label: Control-Group; Type: OTHER; Interventions: Other: Control-Group | Intervention Type: DEVICE; Name: cervical pessary; Assigned to Arm(s): Cervical Pessary-Group | Intervention Type: OTHER; Name: Control-Group; Assigned to Arm(s): Control-Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Case-Management & Environmental Support to Sustain Weight Loss & Reduce CHD Risk
Brief Summary: Physician-based primary care has thus far failed to address the obesity epidemic. In this randomized clinical trial of 200 obese patients with heart disease risk factors, the investigators will evaluate the impact of nurse and dietitian case management on weight loss and weight maintenance, as an adjunct to physician care. In addition, the investigators will test the incremental benefit of an environmental support strategy using community health workers to help patients navigate their home and neighborhood environments to achieve weight loss. The innovative intervention model developed and evaluated in this project has the potential to provide a blueprint for successful primary care-based obesity services


Options:
A: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support for Increased Physical Activity | Intervention Type: BEHAVIORAL; Name: Support for Increased Physical Activity; Assigned to Arm(s): B
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 2
C: Arm Label: Case-Management for Behavior Change; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Case-Management plus Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Usual Primary Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Intervention Type: BEHAVIORAL; Name: Vivamos Activos Fair Oaks Program; Assigned to Arm(s): Case-Management for Behavior Change, Case-Management plus Home Visits, Usual Primary Care
D: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Case-Management & Environmental Support to Sustain Weight Loss & Reduce CHD Risk
Brief Summary: Physician-based primary care has thus far failed to address the obesity epidemic. In this randomized clinical trial of 200 obese patients with heart disease risk factors, the investigators will evaluate the impact of nurse and dietitian case management on weight loss and weight maintenance, as an adjunct to physician care. In addition, the investigators will test the incremental benefit of an environmental support strategy using community health workers to help patients navigate their home and neighborhood environments to achieve weight loss. The innovative intervention model developed and evaluated in this project has the potential to provide a blueprint for successful primary care-based obesity services


Options:
A: Arm Label: Case-Management for Behavior Change; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Case-Management plus Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Arm Label: Usual Primary Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Vivamos Activos Fair Oaks Program | Intervention Type: BEHAVIORAL; Name: Vivamos Activos Fair Oaks Program; Assigned to Arm(s): Case-Management for Behavior Change, Case-Management plus Home Visits, Usual Primary Care
B: Arm Label: Conventional Health Promotion Education (CHPE).; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CHPE | Arm Label: PRECEDE HPE model; Type: EXPERIMENTAL; Interventions: Behavioral: PRECEDE HPE model | Intervention Type: BEHAVIORAL; Name: PRECEDE HPE model; Assigned to Arm(s): PRECEDE HPE model | Intervention Type: BEHAVIORAL; Name: CHPE; Assigned to Arm(s): Conventional Health Promotion Education (CHPE).
C: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program (SM) | Arm Label: Care Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Care management program (CM) | Intervention Type: BEHAVIORAL; Name: Self-management program (SM); Assigned to Arm(s): Self-Management Program | Intervention Type: BEHAVIORAL; Name: Care management program (CM); Assigned to Arm(s): Care Management Program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Brief Summary: Compare efficacy and safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with a primary efficacy endpoint of 6-month seizure freedom. Noninferiority design to show a similar risk/benefit balance between Lacosamide (LCM) and Carbamazepine-CR (CBZ-CR).


Options:
A: Arm Label: Lacosamide; Type: EXPERIMENTAL; Interventions: Drug: Lacosamide | Arm Label: Carbamazepine-Controlled Release (CBZ-CR); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine-Controlled Release | Intervention Type: DRUG; Name: Lacosamide; Assigned to Arm(s): Lacosamide | Intervention Type: DRUG; Name: Carbamazepine-Controlled Release; Assigned to Arm(s): Carbamazepine-Controlled Release (CBZ-CR)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): 1
C: Arm Label: Healthy control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Carbamazepine group; Type: EXPERIMENTAL; Interventions: Drug: Carbamazepine | Arm Label: Oxcarbazepine group; Type: EXPERIMENTAL; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine group | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine group
D: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Options:
A: Arm Label: Assessment Only (ASSESS); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Self-Help (GENERIC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GENERIC | Arm Label: Targeted Self-Help (eTARGET); Type: EXPERIMENTAL; Interventions: Behavioral: eTARGET | Intervention Type: BEHAVIORAL; Name: GENERIC; Assigned to Arm(s): Generic Self-Help (GENERIC) | Intervention Type: BEHAVIORAL; Name: eTARGET; Assigned to Arm(s): Targeted Self-Help (eTARGET)
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Options:
A: Arm Label: Bupropion SR; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: smoking cessation counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Behavioral: smoking cessation counseling | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: smoking cessation counseling; Assigned to Arm(s): Bupropion SR, Placebo
B: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Options:
A: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
C: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
D: Arm Label: tobacco cigarette; Type: ACTIVE_COMPARATOR; Interventions: Other: Tobacco cigarette | Arm Label: e.cigarettes + 16mg nicotine & flavor; Type: ACTIVE_COMPARATOR; Interventions: Device: electronic cigarette + 16mg nicotine & flavor | Arm Label: e.cigarettes + 0mg nicotine & flavour; Type: ACTIVE_COMPARATOR; Interventions: Other: electronic cigarette + 0mg nicotine & flavor | Intervention Type: DEVICE; Name: electronic cigarette + 16mg nicotine & flavor; Assigned to Arm(s): e.cigarettes + 16mg nicotine & flavor | Intervention Type: OTHER; Name: electronic cigarette + 0mg nicotine & flavor; Assigned to Arm(s): e.cigarettes + 0mg nicotine & flavour | Intervention Type: OTHER; Name: Tobacco cigarette; Assigned to Arm(s): tobacco cigarette

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Options:
A: Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
C: Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Objective of this study is to introduce a practically feasible multifaceted intervention in the preadmission clinic to help reduce smoking in preoperative surgical patients. The investigators aim to study the effectiveness of such a program in promoting positive change in smoking behavior among patients before surgery. The forced abstinence enforced on patients during hospital stay for their surgery can also be used to help smokers remain tobacco free long term. A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment.


Options:
A: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C